TP53 and myelodysplastic syndrome: Also, clinical trials exploring APR-246, a mutant P53 activator, are underway (NCT03931291); recently, in 2020, FDA granted breakthrough therapy designation for APR-246 in Combination with Azacitidine for the treatment of MDS with a TP53 Mutation (87).